All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 1 November 20263 min read

Wockhardt (WOCKPHARMA) Q1 FY27 Swings to Profit on Biotech Surge, But Margins Soften

Wockhardt's Q1 FY27 shows a dramatic profit turnaround, yet a sequential margin dip hints at costs ahead for its landmark antibiotic launch.

By Abhinav Singhvi, Founder & CEO Hexawealth · Created 1 November 2026

Wockhardt swung to a ₹107 crore profit in Q1 FY27 from a loss a year ago, driven by 26% revenue growth and a 112% surge in biotech. However, profit margins contracted from the previous quarter as the company prepares for the costly launch of its novel antibiotic Zaynich.

For Wockhardt, the first quarter of FY27 was a story of two recoveries. The headline is a clean escape from last year's deep loss, powered by a booming biotech division. Yet, the path forward is marked by a sequential profit dip, a sign of the investment phase beginning for its historic new antibiotic.

Revenue grew 25.9% year-on-year to ₹929 crore, while profit swung to ₹107 crore from a ₹108 crore loss. This turnaround is stark against the year-ago quarter, which was weighed down by a ₹97 crore exceptional impairment from exiting its US generics business, as reported by The Week. Strip that out, and the underlying recovery from a smaller loss is still solid, driven by operating leverage as expenses grew at less than half the rate of sales.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ1 FY26 738, Q2 FY26 782, Q3 FY26 888, Q4 FY26 965, Q1 FY27 929. Q1 FY26 -108, Q2 FY26 82, Q3 FY26 61, Q4 FY26 164, Q1 FY27 107-2k-1k01k2kQ1 '26Q2 '26Q3 '26Q4 '26Q1 '27
  • Revenue (₹ Cr), Q1 FY26: 738
  • Revenue (₹ Cr), Q2 FY26: 782
  • Revenue (₹ Cr), Q3 FY26: 888
  • Revenue (₹ Cr), Q4 FY26: 965
  • Revenue (₹ Cr), Q1 FY27: 929
  • Profit (₹ Cr), Q1 FY26: -108
  • Profit (₹ Cr), Q2 FY26: 82
  • Profit (₹ Cr), Q3 FY26: 61
  • Profit (₹ Cr), Q4 FY26: 164
  • Profit (₹ Cr), Q1 FY27: 107

Revenue (₹ Cr)

Revenue (₹ Cr)Q1 FY26 738, Q2 FY26 782, Q3 FY26 888, Q4 FY26 965, Q1 FY27 92905001,0001,5002,000Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
  • Revenue (₹ Cr), Q1 FY26: 738
  • Revenue (₹ Cr), Q2 FY26: 782
  • Revenue (₹ Cr), Q3 FY26: 888
  • Revenue (₹ Cr), Q4 FY26: 965
  • Revenue (₹ Cr), Q1 FY27: 929

Profit (₹ Cr)

Profit (₹ Cr)Q1 FY26 -108, Q2 FY26 82, Q3 FY26 61, Q4 FY26 164, Q1 FY27 107-200-1000100200Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
  • Profit (₹ Cr), Q1 FY26: -108
  • Profit (₹ Cr), Q2 FY26: 82
  • Profit (₹ Cr), Q3 FY26: 61
  • Profit (₹ Cr), Q4 FY26: 164
  • Profit (₹ Cr), Q1 FY27: 107

Net Profit Margin (%)

Net Profit Margin (%)Q1 FY26 -14.6, Q2 FY26 10.5, Q3 FY26 6.9, Q4 FY26 17.0, Q1 FY27 11.5-20%-10%0%10%20%Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
  • Net Profit Margin (%), Q1 FY26: -14.6
  • Net Profit Margin (%), Q2 FY26: 10.5
  • Net Profit Margin (%), Q3 FY26: 6.9
  • Net Profit Margin (%), Q4 FY26: 17.0
  • Net Profit Margin (%), Q1 FY27: 11.5
MetricCurrentQ1 FY27PreviousQ4 FY26Same quarter LYQ1 FY26
Revenue (₹ Cr)
929YoY +26%
965
738
Profit (₹ Cr)
107YoY +199%
164
-108
Net Profit Margin (%)
11.5YoY +179%
17.0
-14.6

Sequentially, revenue dipped 3.7% and profit fell 34.8%. The net profit margin contracted 550 basis points from the March quarter's 17%. Reports from StockWatch suggest this is typical post-year-end normalization, not a business deterioration. The real story is the year-on-year climb.

The Biotech Engine Fires Up

The core driver was the biotech segment, which grew 112% year-on-year to ₹236 crore, according to CNBC-TV18. Emerging markets, particularly in Latin America and Asia, led this charge with 146% growth, fueled by insulin products and new distribution deals. The UK and Ireland regions also posted steady growth, while India's branded business rose 21%.

This performance underscores a strategic shift. Wockhardt is harvesting years of investment, with its vertically integrated biotech infrastructure now delivering high-margin sales. It provides the cash flow to fund the next ambitious chapter.

Live Chart

· WOCKPHARMA

(BSE)

ISIN: INE049B01025

The Zaynich Investment Phase Begins

The quarter's margin contraction offers a first glimpse of that next chapter. In May 2026, Wockhardt received US FDA approval for Zaynich, the first India-discovered novel antibiotic to achieve this milestone. While not yet launched, management has flagged that pre-launch and commercialization costs will create a minor negative bottom-line impact over the next 12-18 months, as noted in public reports.

The company is building a specialized US team and scaling up for a launch targeted for early 2027. The market potential is vast, with peak sales guidance of $1.5-2 billion, but the near-term financial picture will reflect these investments. The sequential profit dip from Q4's seasonally strong performance may be a pattern as these costs ramp up.

Key Points

  • Wockhardt's consolidated profit swung to ₹107 crore in Q1 FY27 from a ₹108 crore loss a year ago, aided by the absence of a prior-year exceptional charge.
  • Revenue grew 25.9% YoY to ₹929 crore, propelled by a 112% surge in biotech operations across emerging markets.
  • Sequentially, net profit margin fell to 11.5% from 17.0%, reflecting both normal seasonality and the onset of investment for the Zaynich launch.
  • The company is targeting a US launch for its FDA-approved antibiotic Zaynich in early 2027, with management guiding for a temporary earnings drag from launch costs over the next 12-18 months.
  • The stock trades at a significant premium to the industry, with a P/E of 89.5, pricing in the future success of its novel antibiotic pipeline.

Hexa Perspective

The quarter confirms the operating turnaround is real. The base business, especially biotech, is generating strong growth and cash. This foundation is critical because it must now carry the company through the costly commercialization of Zaynich.

Investors are being asked to pay for a future that is still being written. The current valuation embeds immense expectations for Zaynich's success. The next few quarters will be a balancing act: demonstrating that the core business's momentum can offset the planned investment drag, while hitting launch milestones for the antibiotic without delays or cost overruns. Execution on both fronts will decide if the premium is justified.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Frequently asked questions

What were Wockhardt's Q1 FY27 results?
Wockhardt reported a consolidated profit of ₹107 crore for Q1 FY27, a significant turnaround from a loss of ₹108 crore in the same quarter last year. Revenue grew 25.9% year-on-year to ₹929 crore. The net profit margin for the quarter was 11.5%.
Did Wockhardt's profit rise or fall in Q1 FY27?
Wockhardt's profit rose dramatically on a year-on-year basis, swinging to a ₹107 crore profit from a ₹108 crore loss in Q1 FY26. However, profit fell 34.8% compared to the previous quarter (Q4 FY26), which had a profit of ₹164 crore.
What is Wockhardt's revenue for Q1 FY27?
Wockhardt's consolidated revenue for the first quarter of FY27 (ended June 2026) was ₹929 crore. This represents a 25.9% increase from the ₹738 crore reported in the same quarter of the prior year.
What drove Wockhardt's revenue growth in Q1?
The growth was led by Wockhardt's biotech operations, which surged 112% year-on-year to ₹236 crore, as reported by CNBC-TV18. Emerging markets, particularly for insulin products, were the key driver, along with steady growth in the UK, Ireland, and India's branded business.
Why did Wockhardt's net profit margin decline sequentially?
Wockhardt's net profit margin fell to 11.5% in Q1 FY27 from 17.0% in Q4 FY26. This is attributed to typical post-year-end quarter normalization and the early stages of investment for the commercial launch of its novel antibiotic Zaynich, which management expects to pressure margins temporarily.
What is the update on Wockhardt's new antibiotic Zaynich?
Zaynich received US FDA and Indian regulatory approvals in May 2026. Wockhardt is targeting a US launch in early 2027. Management has indicated that pre-launch and commercialization costs will create a minor negative impact on earnings for the next 12-18 months before the drug contributes meaningfully to revenue.
What is Wockhardt's guidance for the Zaynich launch?
While not providing specific quarterly targets, Wockhardt's management has guided that the Zaynich business will run at a slight loss for 12 to 18 months post-launch before breaking even. They have provided peak sales guidance of $1.5-2 billion for the drug globally.
How is Wockhardt's debt and balance sheet position?
Wockhardt's debt-to-equity ratio stands at 0.43, indicating a manageable level of leverage. Analysis from SAHI notes the company has completed a painful deleveraging phase and is now generating cash flows from its high-margin intellectual property to fund future growth.
What is Wockhardt's current valuation?
Wockhardt trades at a P/E ratio of 89.5, which is a 137.8% premium to the industry P/E of 37.6. This elevated valuation reflects market expectations for the future success and revenue from its novel antibiotic pipeline, particularly Zaynich.
How did the stock react to the Q1 FY27 results?
On the day of the results announcement (August 10, 2026), Wockhardt's stock closed at ₹1,932.7. The stock had risen approximately 6.7% in the month leading into the print, indicating some anticipation of the positive year-on-year turnaround.